Stephanie Schultz

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Jul 5, 2023 | biorxiv.org | Stephanie Schultz |Lei Liu |Aaron Schultz |Colleen M. Fitzpatrick

AbstractBackground: The balance between production, clearance, and toxicity of Aβ peptides is central to Alzheimer's disease (AD) pathobiology. Though highly variable in terms of age at symptom onset (AAO), hundreds of variants in PSEN1 cause autosomal dominant forms of AD (ADAD) with nearly complete penetrance.